Titre:
  • A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Auteur:Lalami, Yassine; Garcia, Camilo; Flamen, Patrick; Ameye, Lieveke; Paesmans, M.; Awada, Ahmad
Informations sur la publication:Head & neck
Statut de publication:A Paraître, 2015
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:FDG PET
Sorafenib
antiangiogenic drugs
head and neck cancer
Langue:Anglais
Identificateurs:urn:issn:1043-3074
info:doi/10.1002/hed.23898
info:pmid/25332069